We are a University of Arizona spin-off company with a presence in the Phoenix Biomedical Campus. Our team has more than 30 years of FAK research leadership and therapeutic development, with core competencies in pharmacology and drug discovery, especially structure-based drug design and computational drug discovery. Over the last 4 years, we have developed a focus on structure-based drug design to complement and extend our cancer biology capabilities. In the future, we plan to continue the development of FAK-related drugs to provide new therapies for cancers and other diseases that lack effective treatment options.